The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
Executive Summary
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March
You may also be interested in...
Industry Wants More Transparency From Agency On REMS Determinations
SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions
Industry Wants More Transparency From Agency On REMS Determinations
SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions
Post-Marketing Trial Key To Saxagliptin Approval – And Commercial Potential
Bristol-Myers Squibb and AstraZeneca will need to design a precedent-setting cardiovascular outcomes study for saxagliptin before the drug will be approved by the agency